Insulet (PODD) Rolls Out Omnipod Discover Nationwide, Is The Stock Still Cheap?
Insulet (PODD) just moved Omnipod Discover from limited rollout to full U.S. market release, putting its web based diabetes data platform in front of every Omnipod 5 user nationwide.
Recent trading suggests the Omnipod Discover rollout may be shifting sentiment toward Insulet, with a 1 day share price return of 3.35% and a 30 day gain of 5.95%, even though year to date share price performance is down 50.58% and the 1 year total shareholder return has declined 55.55%. This points to short term momentum picking up after a difficult stretch for longer term holders.
Scan how Insulet compares to other potential rebound candidates by reviewing the hand picked 29 high quality undervalued stocks that currently pair solid fundamentals with discounted valuations.
Insulet now trades well below both analyst targets and one intrinsic value estimate, even after the Omnipod Discover news bounce. So where does a reasonable fair value actually land in that gap?
Most Popular Narrative: 3% Undervalued
Against Insulet's last close at $139.81, the most followed narrative anchors fair value at $144, leaving a narrow discount that still leans in favor of the stock on this framework.
Although type 2 adoption is picking up from a low base with AID use below 5% in a market size above $12b, primary care physicians may face workflow and training constraints even with guideline support. This could restrain the pace of type 2 growth and soften the impact on total revenue and earnings.
See why 0 investors see Insulet as 3% undervalued.
Result: Fair Value of $144 (UNDERVALUED)
Still, higher type 2 diabetes attrition and ongoing Omnipod related legal actions could challenge Insulet’s fair value narrative if they weigh on utilization and costs.
Find out about the key risks to this Insulet narrative.
Next Steps
Sentiment around Insulet is mixed, and that is exactly when fresh data can help most. Take a closer look at the underlying positives and see how they line up with your expectations by reviewing the 3 key rewards
Hunting For More Ideas Beyond Insulet?
If Insulet has your attention, do not stop there. Use the Simply Wall St screener to surface other opportunities that fit the way you like to invest.
- Target resilient cash generators by scanning companies with strong financial buffers using the list of solid balance sheet and fundamentals (25 results).
- Seek asymmetric upside by reviewing the 20 high quality undiscovered gems that have robust fundamentals yet still fly under most investors' radar.
- Dial down portfolio stress by focusing on the 31 resilient stocks with low risk scores that pair steadier profiles with more controlled downside.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com